Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Precision diagnosis for tailored therapy in acute lymphoblastic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 121
Rating:

Dr Jean-Pierre Bourquin - University Children’s Hospital, Zurich, Switzerland

Dr Jean-Pierre Bourquin talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the use of novel functional assays to evaluate a patient's drug response.

He discusses the functionality of these assays, which include identifying the sensitivity and resistance profiles of a patient's leukaemia cells.

Dr Bourquin concludes by stating that patient subsets need more precise interrogation and an improved regulatory framework for clinical trials in this disease type.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation